EGFR and non-small cell lung carcinoma: The approval of first- and second-generation EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib, and afatinib in the 2000s, resulted in substantial improvements in clinical outcomes over chemotherapy in EGFRm NSCLC.9-12 Subsequently, the third-generation EGFR-TKI osimertinib was first approved in 2015 as a monotherapy.13 In 2024, osimertinib plus chemotherapy and amivantamab plus lazertinib, were approved for 1L EGFRm NSCLC13,14; however, so far, only amivantamab plus lazertinib has shown a statistically significant benefit in overall survival.15,16